Sign in to view content

Evaluating Clinical Signs of Regression in Eyes Treated With Intravitreal Bevacizumab for Type 1 Retinopathy of Prematurity

Yuxi Zheng, MD

Video
Published 2025

Related

The incidence and timing of treatment-requiring retinopathy of prematurity (ROP) in nanopremature and micropremature infants in the United States
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2023
Laser Photocoagulation for Type 2 Retinopathy of Prematurity (ROP) or Less: When and Why?
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2020
Potential Safety Concerns of Bevacizumab for Retinopathy of Prematurity
Robert L. Avery, MD
Annual Meeting Talks
2016

Category: Pediatric Retina - ROP

See more